PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies.
A Dominant Bio-Research Presence Sought
Learn to instill quality and efficiencies into a clinical database from beginning to end
Dante Labs introduced a new Whole Genome Sequencing of 130X coverage for the Exome and 30X coverage for DNA's non-coding regions
Vibcare Pharma Pvt. Ltd, a pharmaceutical company based in Panchkula, is offering well thought out, growth-oriented PCD pharma franchise program nationally.
Vibcare Pharma Pvt. Ltd, a pharmaceutical company with an international footing, is providing PCD pharma franchisee programs at the national scale with the promise of collective growth.
River Oaks Tower to be renamed T-Mobile Tower
Vibcare Pharma Pvt. Ltd, a pharmaceutical company with over four decades of experience, is providing lucrative pharma franchisee programs to interested parties on a national scale.
This presentation, the first in a 4-part webinar series examining supplier quality management for the pharmaceutical and medical device industries, will explore the business and regulatory drivers for implementing solutions that address key quality and compliance needs, and extended enterprise supply chain requirements.
CNS drug developers have to focus on physical safety and efficacy first, especially when developing products for rare disorders or diagnoses that are often unresponsive to other therapies. Although these products rarely have notable CNS mediated side effects, they fall under the FDA's requirement for an abuse potential assessment because they cross the blood-brain barrier.
Interest in the medical use of cannabis and cannabinoids continues to grow as patients and caregivers consider this option for treatment of unmet medical needs. Ever growing efforts to legalize cannabinoids in the US and Canada are creating an increased need to evaluate safe and effective use.
According to the new market research report launched by Inkwood Research, The Global Antithrombotic Drugs market was valued at nearly $24900 million in 2017 and is anticipated to reach $45100 million by 2026, growing at an estimated CAGR of 6.83%, during the forecast period 2018-2026.